If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
The first advances in wound care in this era began with the work of Ignaz Philipp Semmelweis, a Hungarian obstetrician who discovered how hand washing and cleanliness in general in medical procedures prevents maternal deaths. Semmelweis's work was furthered by an English surgeon, Joseph Lister, who in 1860s began treating his surgical gauze with carbolic acid, known today as phenol, and subsequently dropped his surgical team's mortality rate by 45%. Building on the success of Lister's pretreated surgical gauze, Robert Wood Johnson I, co-founder of Johnson & Johnson, began in the 1890s producing gauze and wound dressings sterilized with dry heat, steam, and pressure. These innovations in wound-site dressings marked the first major steps forward in the field since the advances of the Egyptians and Greeks centuries earlier. In 1886, Ernst von Bergmann introduced heat sterilization of surgical instruments, which marked the beginning of aseptic surgery and significantly reduced the frequency of infections. Conrad Brunner did extensive research into wound management and experimentation with wound disinfection methods, publishing his comprehensive Erfahrungen und Studien über Wundinfektion und Wundbehandlung in 1898. That same year, Paul Leopold Friedrich introduced wound excision and experimentally showed that excision of open wounds substantially reduced the risk of infection. The next advances would arise from the development of polymer synthetics for wound dressings and the "rediscovery" of moist wound-site care protocols in the mid 20th century.
Central Institute for Research on Buffaloes, Hisar, a publicly funded, institute for water buffalo research. It is located 170 kilometres (110 mi) from Delhi, at Hisar in the north Indian state of Haryana. It has a sub-campus, Bir Dosanjh, at Nabha. CIRB operates a nationwide network of 10 research centres working on breed improvement of the 7 main native breeds. CIRB, with over 20 laboratories for buffalo research, is the world's largest buffalo research institute with the widest range of breeds under study. With the aim of improving breeds and dissemination of information, CIRB has sold over 1,000 bulls, conducted ~200,000 artificial insemination in the field for the farmers' buffaloes with a 41% conception rate, distributed ~520,000 progeny tested frozen semen kits to 45,000 farmers and over 250 institutes, imparted training to several thousand farmers on advanced buffalo husbandry, and created the world's first online Buffalopedia in several languages. It has a large research partner network across India and the globe. It is the second institute to successfully clone a buffalo in 2016, after the first successful cloning was achieved by the National Dairy Research Institute, Karnal in 2010. In July 2017, the Indian Council of Agricultural Research ranked CIRB Hisar as India's number one Buffalo research institute for the year 2016–17. India has 58% the world's buffaloes and 35% of India's cattle are buffaloes. Buffalo milk is 70% of the total milk yield in India, with its national gross domestic product (GDP) share being larger than wheat and rice combined.
== Causes == The development of vitiligo is linked to aberrant attachments between melanocytes (which produce melanin) and laminins, a kind of glycoprotein. When the basement membrane (the fibrous layer between cells and adjacent connective tissue) becomes enriched in laminin-332, melanocytes attach to that protein instead of the normal laminin-211 (via an integrin receptor instead of dystroglycan). Rather than disappearing, melanocytes appear to dedifferentiate and thus lose the ability to produce pigment, altering the actin cytoskeleton of affected cells. Melanocyte loss may also be caused by the activation of the signaling pathway formed by Janus kinases (JAKs) and signal transducer and activator of transcription proteins (STATs), being triggered by T cells and creating a positive feedback loop with interferon-gamma (IFN-γ) chemokines (a form of cytokine signaling protein) secreted by keratinocytes, the primary cell type of the epidermis. According to one study, segmental vitiligo (SV) is linked to the dysfunction of sympathetic nerves and demonstrates increased adrenoceptor responses in the affected areas as well as three times higher local blood flow. Meanwhile, a blood flow increase of about 1.5 times occurs in the more common nonsegmental vitiligo (NSV). The disorder has occurred in recipients of bone marrow and lymphocytes from donors with vitiligo.
== Epidemiology == There are only about 14 reported cases of Morvan's syndrome in the English literature. With only a limited number of reported cases, the complete spectrum of the central nervous system (CNS) symptomatology has not been well established. The natural history of Morvan's is highly variable. Two cases have been reported to remit spontaneously. Others have required a combination of plasmapheresis and long term immunosuppression, although in one of these cases the patient died shortly after receiving plasma exchange (PE). Other fatalities without remission have been described by, amongst others, Morvan himself.
Sources: en.wikipedia.org
==== Pharmacokinetics of Quinoline and quinazoline-derivatives ==== Absorption is variable within the group, with tmax ranging from 1–4 hours for Lenvatinib to 4–10 hours for cabozatinib. Food can slow down the absorption rate but should not affect the extent of the absorption. All drugs have high protein binding, ranging from 90-99%. Vandetanib and cabozatinib are metabolized mainly by CYP3A4, while lenvatinib is metabolized by CYP450 and via other pathways. The drugs are eliminated mostly in faeces, but also in urine. Vandetanib has a half-life of 19 days, while cabozatinib’s half-life is 99 hours.
==== Metabolism ==== Suvorexant is metabolized primarily by hydroxylation via CYP3A enzymes. CYP2C19 also contributes to suvorexant metabolism to a minor extent. The major circulating forms are suvorexant and its metabolite hydroxysuvorexant. The hydroxysuvorexant (M9) metabolite is not expected to be pharmacologically active. It showed 10-fold lower affinity for the orexin receptors than suvorexant in vitro, was a substrate for P-glycoprotein making it unlikely to cross the blood–brain barrier, and did not show sedative effects in animal studies. Suvorexant also has several other minor metabolites.
According to Google patent search, Masliah's name appears on 28 patents, including several patents filed by Prothena Biosciences, as well as earlier patents filed in conjunction with UCSD for drugs that target synucleopathies. Research trials on the drugs cerebrolysin and minzasolmin were also found to be based on questionable data from Masliah's lab. Masliah co-authored 21 papers on the pig brain extract cerebrolysin, eight of which have been discovered to have issues. Cerebrolysin is marketed as containing "neurotrophic peptides" but researchers using high performance liquid chromatography found that it does not contain peptides, and is largely composed of amino acids and salt, with some trace protein fragments. Some of the fraudulent papers on cerebrolysin co-authored by Masliah appear to have been quite influential in boosting interest in cerebrolysin, which is used today in countries like Russia to treat stroke, dementia, and other conditions. Masliah received funding for many of his cerebrolysin studies from the maker of cerebrolysin, EVER Pharma, and collaborated with Herbert Moessler, former general manager at EVER Pharma, who incidentally has 19 of his own papers flagged for anomalies. Moessler and Masliah started a company, Neuropore, to investigate the drug minzasolmin in 2008. On December 16, 2024 UCB reported that a phase II clinical trial on minzasolmin involving 496 people showed that minzasolmin failed to demonstrate superiority over placebo in both primary and secondary endpoints. Masliah has not publicly commented on any of the findings against him.
Sources: en.wikipedia.org
In September 2024, following the resolution of a prolonged pay dispute, it was announced that the term "junior doctor" within the NHS would be replaced with "resident doctor." This change was set to take effect on Wednesday, 18 September 2024.
=== Lasso peptides === Lasso peptides are short peptides containing an N-terminal macrolactam macrocycle "ring" through which a linear C-terminal "tail" is threaded. Because of this threaded-loop topology, these peptides resemble lassos, giving rise to their name. They are a member of a larger class of amino-acid-based lasso structures. Additionally, lasso peptides are formally rotaxanes. The biosynthesis of lasso peptides is different from other RiPPs because the N-terminal leader peptide is cleaved first by a dedicated peptidase. After the cleavage, a lasso cyclase enzyme forms an isopeptide bond between the N-terminal amine of the first amino acid of the peptide and the carboxylate side chain of an aspartate or glutamate residue. This creates a constrained lasso peptide with three sections: the ring, the loop, and the tail. The ring is typically 7 to 9 amino acids long, while the C-terminal tail ranges from 7 to 15 amino acids in length. The first amino acid of lasso peptides is almost invariably glycine or cysteine, with mutations at this site not being tolerated by known enzymes. Thus, bioinformatics-based approaches to lasso peptide discovery have thus used this as a constraint. However, some lasso peptides were recently discovered that also contain serine, alanine, or tryptophan as their first residue. Other bioinformatics approaches use the peptidase involved in lasso peptide biosynthesis to discover new lasso peptide biosynthetic gene clusters.
=== As a biosynthetic intermediate === In higher eukaryotes, δ-aminolevulinic acid, the key precursor to porphyrins, is biosynthesized from glycine and succinyl-CoA by the enzyme ALA synthase. Glycine provides the central C2N subunit of all purines.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.